论文部分内容阅读
目的:探讨MMP-9与高血压合并糖尿病患者颈动脉硬化的相关性,为临床治疗提供参考。方法:20例门诊高血压合并糖尿病和健康体检人20例都检测SBP(舒张压)、DBP(收缩压)及MMP-9含量水平,同时相关患者还采用厄贝沙坦治疗。结果:经过治疗后,观察组SBP、DBP较治疗前明显下降(P<0·05),血清MMP-9水平也较治疗前明显降低(P<0·05),达到了健康个体的SBP、DBP和血清MMP-9水平。结论:厄贝沙坦可改善高血压合并糖尿病颈动脉弹性,阻止动脉粥样硬化的发生、发展并能稳定粥样斑块,除降压机制外,还可以通过降低MMP-9以改善颈动脉的结构与功能而起到降压作用。
Objective: To investigate the correlation between MMP-9 and carotid atherosclerosis in patients with hypertension and diabetes mellitus, and to provide reference for clinical treatment. Methods: Twenty patients (20 diabetics), DBP (systolic blood pressure) and MMP-9 levels were measured in 20 outpatients with hypertension and diabetes. All the patients were treated with irbesartan. Results: After treatment, SBP and DBP in the observation group were significantly lower than those before treatment (P <0.05), serum MMP-9 level was also significantly lower than before treatment (P <0 · 05), reaching SBP in healthy individuals, DBP and serum MMP-9 levels. Conclusion: Irbesartan can improve the carotid artery elasticity and prevent the development of atherosclerosis in hypertensive patients with diabetes mellitus, and it can stabilize the atherosclerotic plaque. In addition to the antihypertensive mechanism, irbesartan can improve the carotid artery by reducing MMP-9 The structure and function of the anti-pressure effect.